
    
      This investigator-initiated study is being conducted to evaluate whether the investigational
      drug, Dovitinib, can shrink or slow the growth of cancer in patients with certain types of
      neuroendocrine tumors (advanced malignant pheochromocytoma or paraganglioma). The primary
      endpoint will be response rate (Complete + Partial Response) determined by RECIST v 1.1. 25
      subjects will be enrolled on this study at the University of Pennsylvania.
    
  